Denali Therapeutics Inc. Earnings Per Share (Basic)
Denali Therapeutics Inc. (DNLI) reported Earnings Per Share (Basic) of -$0.68 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Denali Therapeutics Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.68.
- Denali Therapeutics Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.69.
- Denali Therapeutics Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.73.
- Denali Therapeutics Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.74.
- Denali Therapeutics Inc. earnings per share, basic for fiscal 2025 was -$2.97.
- Denali Therapeutics Inc. earnings per share, basic for fiscal 2024 was -$2.57.
- Denali Therapeutics Inc. earnings per share, basic for fiscal 2023 was -$1.06.
- Denali Therapeutics Inc. earnings per share, basic for fiscal 2022 was -$2.60.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.68 10-Q · filed 2026-08-06 | -$1.37 10-Q · filed 2026-08-06 | -$2.10 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.83 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.69 10-Q · filed 2026-05-07 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.15 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.88 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.47 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.19 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.97 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.74 10-Q · filed 2025-11-06 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.24 10-Q · filed 2025-11-06 | -$2.91 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.72 10-Q · filed 2026-08-06 | -$1.50 10-Q · filed 2026-08-06 | -$2.18 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.81 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.78 10-Q · filed 2026-05-07 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.08 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.67 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.67 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.57 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.63 10-Q · filed 2025-11-06 | -$1.22 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.89 10-Q · filed 2025-11-06 | -$2.73 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2024-06-30 | -$0.59 10-Q · filed 2025-08-11 | -$1.26 10-Q · filed 2025-08-11 | -$2.10 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.83 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2024-03-31 | -$0.68 10-Q · filed 2025-05-06 | -$1.54 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.26 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-12-31 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.59 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.06 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.72 10-Q · filed 2024-11-06 | $0.61 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.19 10-Q · filed 2024-11-06 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-06-30 | $1.34 10-Q · filed 2024-08-01 | $0.54 10-Q · filed 2024-08-01 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-03-31 | -$0.80 10-Q · filed 2024-05-07 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.38 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.87 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-12-31 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.60 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.84 10-Q · filed 2023-11-07 | -$1.32 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.85 10-Q · filed 2023-11-07 | -$2.46 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-06-30 | -$0.48 10-Q · filed 2023-08-08 | -$1.01 10-Q · filed 2023-08-08 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.32 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-03-31 | -$0.53 10-Q · filed 2023-05-08 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.34 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2021-12-31 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.39 10-K · filed 2024-02-28 |
| 2021-09-30 | -$0.69 10-Q · filed 2022-11-03 | -$1.20 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.77 10-Q · filed 2022-11-03 | $0.24 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-06-30 | -$0.50 10-Q · filed 2022-08-08 | -$1.08 10-Q · filed 2022-08-08 | $0.94 derived: net income ÷ weighted average shares · filed 2023-02-27 | $0.48 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-03-31 | -$0.58 10-Q · filed 2022-05-05 | $1.45 derived: net income ÷ weighted average shares · filed 2023-02-27 | $1.00 derived: net income ÷ weighted average shares · filed 2023-02-27 | $0.51 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2020-12-31 | $2.04 derived: net income ÷ weighted average shares · filed 2023-02-27 | $1.64 derived: net income ÷ weighted average shares · filed 2023-02-27 | $1.15 derived: net income ÷ weighted average shares · filed 2023-02-27 | $0.65 10-K · filed 2023-02-27 |
| 2020-09-30 | -$0.54 10-Q · filed 2021-11-04 | -$1.10 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.65 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$0.56 10-Q · filed 2021-08-04 | -$1.11 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | -$0.55 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$2.07 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.82 10-K · filed 2020-02-27 | -$0.39 10-K · filed 2021-02-26 | ||
| 2018-09-30 | -$0.38 10-K · filed 2020-02-27 | |||
| 2018-06-30 | -$0.59 10-K · filed 2020-02-27 | |||
| 2018-03-31 | -$0.26 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |